In-silico Studies and Biological Activity of Potential BACE-1 Inhibitors.

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Computational Drug Design

Background:

• Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline and dementia.
• Pathological hallmarks of AD include brain lesions and neuronal damage resulting from aggregated amyloid precursor protein (APP) fragments.
• Reducing amyloid-beta (Aβ) load by inhibiting secretase enzymes is a key therapeutic strategy for AD.

Purpose of the Study:

• To develop and validate a quantitative structure-activity relationship (QSAR) model for pyrrolidine-based BACE-1 inhibitors.
• To design novel BACE-1 inhibitors using a pharmacophore model and in-silico approaches.
• To identify potent BACE-1 inhibitors with potential therapeutic applications for Alzheimer's disease.

Main Methods:

• A QSAR study was conducted on 55 pyrrolidine-based compounds with BACE-1 inhibitory activity.
• A pharmacophore model was developed and validated with a correlation coefficient (r) of 0.90 and RMSD of 0.87.
• In-silico screening and molecular docking were employed to evaluate potential BACE-1 inhibitors.

Main Results:

• A robust pharmacophore model was successfully developed for BACE-1 inhibitors.
• In-silico screening identified promising drug candidates with high fit values and docking scores.
• Two structurally distinct compounds demonstrated effective binding to the BACE-1 receptor at Asp32 and Thr232 residues.

Conclusions:

• The developed pharmacophore model is effective for designing novel BACE-1 inhibitors.
• An aryl-substituted carbamate compound showed significant inhibitory potential against BACE-1.
• In-vitro assays confirmed potent biological activity (>0.1μM) for the identified compounds, suggesting therapeutic potential for Alzheimer's disease.